News

ivWatch Awarded Patient Safety Solutions Agreement with Premier, Inc.

ivWatch, LLC has been awarded a group purchasing agreement for Patient Safety Solutions with Premier, Inc. to provide more than 4,000 Premier member hospitals with greater access to the only continuous peripheral IV (PIV) site monitoring technology available in the market. The three-year agreement underscores the importance of detecting IV infiltration and extravasation events early to advance patient safety and create a new standard of care.

The new agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for the ivWatch Model 400 system. ivWatch’s one-of-a-kind technology gives hospitals a continuous IV site monitoring solution with two sensor offerings – a reusable fiber optic sensor and a miniaturized disposable LED sensor. Both sensors measure changes in the optical properties of the tissue near an IV insertion site using visible and near-infrared light paired with a proprietary signal processing algorithm to help catch infiltrations early.

“We know that every infiltration is a drug delivery error and ivWatch exists to help eliminate patient harm associated with complications in IV therapy,” said Gary Warren, President and CEO, ivWatch. “We are on a mission to help raise awareness about such an underreported, critical issue associated with IVs. We want to help advocate for patients and partner with hospitals and clinicians to help prevent IV infiltration and extravasation events from happening. We are excited to further our footprint in the United States to the network of Premier hospitals and provide easy access to ivWatch’s innovative IV site monitoring solutions.”

Everyone is familiar with getting an IV, but not everyone knows about the estimated 46 million high-risk peripheral IVs given in the U.S. each year.1 ivWatch is here to partner with and notify clinicians in real-time of any tissue changes around an IV insertion site that indicate a potential infiltration and help hospitals deliver optimal outcomes in vascular therapy.

Premier is a leading healthcare improvement company, uniting an alliance of more than 4,100 U.S. hospitals and approximately 200,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.

Recent News

04/01/2025

ReAlta Life Sciences Announces Appointment of Distinguished Immunologist, Laurie Glimcher, M.D., to Board of Directors

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases,  announced the appointment of Laurie Glimcher, M.D., to its Board of Directors, effective immediately. Dr. Glimcher is a distinguished immunologist widely renowned for her work in cancer

03/31/2025

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process. Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and

03/26/2025

New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation

Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products — making the supply of medicines for US patients and